Immuno-Oncology Summit 2027 | Sponsor & Exhibit

The series

One immuno-oncology summit, three 2027 editions

ImmunoMark is an immuno-oncology summit run in three cities in 2027, and every edition pairs Stream 1, Next-Gen Immuno-Oncology, with Stream 2, Biomarkers & Companion Diagnostics, over two days.

For an IO vendor deciding which immuno-oncology meeting deserves its 2027 event budget, that structure is the point. You are not picking between a therapy meeting and a biomarker meeting: the therapy teams, the translational scientists who measure what those therapies do, and the people who buy the assays are in the same building. The editions differ in date, region and Stream 1 emphasis, which is what this page helps you compare.

3editions in 2027: San Diego, London, Boston

2parallel streams at every edition

20 minpre-scheduled 1:1 meetings, chosen from delegate profiles

200+meetings conducted at London 2026

The differentiator

Why the IO and biomarker overlap matters to your sales team

Most IO deals involve two buying groups: the programme team that owns the molecule and the translational team that has to show it works in patients. ImmunoMark puts both on one floor plan.

An immuno-oncology biomarkers event, not two meetings

Sponsors on Platinum, Gold and Silver choose one stream for their talk, but the booth, the drinks reception and the 1:1 meetings draw on the whole delegate list. One stand reaches both sides of the deal.

Sessions on the boundary

London, Stream 2: Functional T cell Biomarkers for Precision Immuno-Oncology (Marc Vendrell, The University of Edinburgh)
London, Stream 1: Clinical Trial Design in Immunotherapy: Adaptive & Biomarker-Driven Models
San Diego, Stream 2: Decoding Response and Resistance to Immunotherapy in NSCLC Through Integrative Multi-Omic and AI Approaches (Ariel (Yung-Chia) Chen, Johnson & Johnson)

Proof from London 2026

The first edition drew 300+ attendees from 100+ companies, 70% of them senior decision-makers. Its Stream 1 themes ran from IO approaches beyond PD-1/PD-L1 and TCR-T and CAR-T advances to multi-specific antibody engineering and cancer vaccines.

Edition comparison

Immuno-oncology summit 2027 editions compared for IO sponsors

Packages are the same at every edition, so the choice comes down to timing, region and which Stream 1 agenda matches your product.

	San Diego	London	Boston
Dates	10–11 February 2027	3–4 March 2027	June 2027 (dates to follow)
Edition	Launch edition	2nd annual	Launch edition
Delegates	300+ senior attendees expected	400+ target	300+ expected
Delegate base	US West Coast biotech hub	60% UK & Ireland, 40% rest of Europe	US East Coast
Stream 1 emphasis	In vivo cell engineering; NK, TIL and in vivo CAR platforms; neoantigen vaccines; synthetic biology; computational immunology	Myeloid checkpoints; logic-gated CAR-T; allogeneic cell therapy; bispecific and multispecific engagers; combinations	Agenda not yet published
Track record	First edition	London 2026: 300+ attendees, 15–25 meetings per sponsor	First edition
Best for IO sponsors who	sell into US cell and gene engineering programmes early in the budget year	need UK and continental European pipeline, with a year of proof behind the event	want a mid-year US slot after the first two editions

City-level detail for the two published agendas is on our San Diego cancer immunotherapy conference and London cancer immunotherapy conference pages.

Stream 1 themes

Next-gen immuno-oncology congress themes, and where each edition goes deeper

Four themes run through both published Stream 1 agendas. The sessions differ, which lets you match your talk to the edition.

Cell therapy beyond first-generation CAR-T

London: CARKey: A multi-antigen specific logic-gated CAR T platform (John Bridgeman, ImmunoKey Ltd)
San Diego: The Future of In Vivo Cell Engineering and Gene Editing Technologies in Cancer Immunotherapy

Resistance and the tumour microenvironment

London: Keynote: Myeloid-Targeted Immunotherapies: Clinical Lessons from MDS and Solid Tumor Studies (Petri Bono, Faron Pharmaceuticals)
San Diego: Overcoming Resistance Mechanisms to Improve Long-Term Responses to Immunotherapy

Combinations

London: Keynote: Next-Gen Combo Immunotherapies (Ivan Diaz-Padilla, Ipsen)
San Diego: Novel Combination Immunotherapy Strategies for Hard-to-Treat Cancers

AI and computation

London: AI protein design work and our various other digital initiatives (Marc Siggel, Merck KGaA, Darmstadt, Germany)
San Diego: Computational Immunology and Digital Twin Technologies for Precision Cancer Treatment

If you are weighing this against a larger immuno-oncology congress, the trade-off is scale against access: two focused streams, a senior room and meetings you choose in advance, rather than a crowded hall.

Packages

A package plan for IO sponsors across the series

Commit to one lead edition with a Stream 1 talk, then decide whether a second edition is a speaking or a meetings play.

Best fit

Platinum, Stream 1, at your lead edition

The strongest balance of stage time and meetings for an IO vendor at the edition closest to your pipeline.

30-minute Day 1 talk plus Q&A
10 pre-scheduled 1:1 meetings
8 team + 8 client passes, 10 x 6 ft booth
Attendee list a week before

Headline

The one package that spans both streams, for a company selling to IO programme teams and biomarker teams at once. One company per edition.

Welcome speech and 30-minute Day 1 keynote
15 meetings, 20 x 12 ft space
Email to the full pre-qualified database
“Powered by” branding

Exclusive 1:1 Meetings at a second edition

Test a new region without a talk: book meetings, read the room, then decide on a speaking tier next year.

3, 5, 7 or 10 meetings of 20 minutes
2–4 passes plus drinks reception passes
Wishlist and delegate list with contacts

Tier details for each edition: London sponsorship opportunities and San Diego sponsorship opportunities. If your product is closer to immune profiling reagents than therapy services, see the cancer immunology conference page; for Stream 2, the biomarker conference hub. Our guide on how to choose biotech conferences to sponsor covers the wider decision.

Tell us which editions you are considering and we will send the prospectus for each, with Stream 1 slot availability.

Request the prospectus

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

Which ImmunoMark edition should an IO vendor sponsor first?

Start with the edition nearest your pipeline. San Diego (10–11 February 2027) suits vendors selling into US cell and gene engineering programmes. London (3–4 March 2027) suits vendors targeting UK and European teams and has the 2026 edition as a track record. Boston (June 2027) is the launch of a third, US East Coast edition.

Is Stream 1 the same at every edition?

No. Each edition publishes its own agenda. San Diego's Stream 1 leans toward in vivo cell engineering, NK, TIL and in vivo CAR platforms and neoantigen vaccines. London's leans toward myeloid checkpoints, logic-gated CAR-T, allogeneic cell therapy and multispecific engagers. Boston's agenda has not yet been published.

Can we choose Stream 1 at every package level?

Platinum, Gold and Silver sponsors choose their stream. The Headline package spans both streams. Exhibitor, Exclusive 1:1 Meetings and branding packages are not tied to a stream, and 1:1 meetings are chosen from the full delegate list.

Are packages the same across editions?

Yes. Headline, Platinum, Gold, Silver, Exhibitor, Exclusive 1:1 Meetings and branding packages carry the same inclusions at every edition. Ask the sponsorship team about combining editions in one plan.

What did sponsors get from the London 2026 edition?

London 2026 had 300+ attendees from 100+ companies, 70% of them senior decision-makers. More than 200 meetings took place, sponsors held 15–25 meetings each, and title sponsors had 55+ pre-scheduled 1:1 meetings.

Immuno-Oncology Summit 2027: Where IO Vendors Should Sponsor

Get the prospectus and package availability